Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases. The company operates primarily within the biopharmaceutical and drug-device combination industries, leveraging proprietary inhalation technologies to deliver medicines via the pulmonary route. MannKind’s business is centered on improving drug delivery efficiency, patient convenience, and therapeutic outcomes, particularly for chronic conditions requiring frequent dosing.
The company’s core commercial product is Afrezza, a rapid-acting inhaled insulin for adults with diabetes, which represents its primary revenue driver. MannKind also generates revenue through manufacturing services and collaborative agreements using its proprietary Technosphere technology platform. Founded in 1991 by Alfred E. Mann, the company initially focused on medical device innovation before evolving into a biopharmaceutical firm, culminating in the FDA approval of Afrezza in 2014 and subsequent restructuring to focus on pulmonary drug delivery.
Business Operations
MannKind operates through a single primary operating segment focused on the research, development, manufacturing, and commercialization of inhaled pharmaceutical products. Revenue is generated through direct product sales of Afrezza, as well as collaboration and service revenues from development and manufacturing agreements with third parties. The company controls proprietary dry-powder formulation and inhalation technologies, including the Technosphere platform and associated inhaler devices.
Manufacturing operations are largely vertically integrated, with significant production capabilities located in the United States. MannKind also supports partnered programs by providing formulation development, clinical supply manufacturing, and commercial-scale production. Notable partnerships include collaborations for inhaled therapies targeting rare lung diseases, though MannKind generally retains ownership of its core technology assets.
Strategic Position & Investments
Strategically, MannKind is focused on expanding the application of its inhalation technology beyond diabetes into orphan and specialty pulmonary indications. Growth initiatives include advancing a pipeline of inhaled therapeutics, such as clofazimine inhalation suspension for nontuberculous mycobacterial lung disease, and pursuing selective partnerships to share development risk while monetizing its platform.
The company has made targeted investments in internal research and development rather than large-scale acquisitions, emphasizing capital discipline. United Therapeutics Corporation holds a significant equity stake in MannKind and collaborates with the company on inhaled treprostinil programs, representing a strategically important relationship. Emerging areas of focus include inhaled treatments for rare lung diseases and potential expansion into additional endocrine indications.
Geographic Footprint
MannKind is headquartered in the United States, with its principal executive offices in California and primary manufacturing operations in Connecticut. Commercial activities are currently concentrated in North America, where Afrezza is marketed to healthcare providers and patients within the U.S. diabetes market.
Internationally, MannKind’s presence is more limited and primarily partnership-driven, with licensing or distribution arrangements enabling access to select European and global markets. While the company does not maintain extensive overseas manufacturing infrastructure, its technologies and products have international regulatory and commercial relevance through collaborators.
Leadership & Governance
MannKind’s leadership emphasizes operational focus, disciplined capital allocation, and leveraging proprietary technology to address unmet medical needs. Governance reflects a blend of biopharmaceutical, manufacturing, and commercialization expertise, with strategic influence from long-term stakeholders.
Key executives include:
- Michael E. Castagna – Chief Executive Officer
- Matthew J. Pfeffer – Chief Financial Officer
- Dr. David Thomson – President and Chief Operating Officer
- Dr. Steve Hoyt – Chief Scientific Officer
- Kevin McCarthy – General Counsel and Corporate Secretary
The leadership team’s strategic vision centers on sustainable growth through pipeline expansion, operational efficiency, and the long-term value of inhaled drug delivery technologies.